Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against canc…
Biotechnology
US, Woburn [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Replimune Group, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2024 | -3.2400 | -3.051 | 0 | 0 | -215 | -209 | -230 | 0 | -237 | 0 | 59 | 0 |
| 2025 | - | -2.865 | - | 8 | - | -193 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 3.F2X/td> | - | 3.F2X/td> | - | 3.F2X/td> | - | 3.F21/td> | - | 3.F21 | - | 3.F21 |
| 2027 | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2028 | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2029 | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |